Multiply Labs specializes in creating personalized vitamins and supplements tailored to individual health needs. Their process uses advanced technology to analyze factors like age, lifestyle, and health goals, allowing them to formulate effective supplement regimens for each customer. This company primarily targets health-conscious consumers, including fitness enthusiasts and those with specific dietary requirements. Unlike many competitors, Multiply Labs operates on a direct-to-consumer model, selling products through their website and offering subscriptions for a steady revenue stream. Their goal is to provide customized nutritional solutions that enhance individual health and wellness.

Tank Stream Ventures

Y Combinator

Pegasus Tech Ventures

P101 Ventures

CRCM Ventures

Graph Ventures

Pacific 8 Ventures

Lux Capital

Garage Capital

Casdin Capital

Founders Fund

Fifty Years

Healthcare

Consumer Goods

Multiply Labs

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell  Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing. This collaboration will combine LCGM’s world-leading process development expertise with Multiply Labs’ robotic technology. Multiply Labs’ unique approach to cell therapy manufacturing automation focuses on robotic systems that can operate GMP-proven instruments from multiple different vendors. The robots operate instruments, consumables and reagents which are already extensively deployed for cell and gene therapy manufacturing, enabling plug-and-play-like capabilities, and fewer regulatory barriers, as no major process changes are required for robotic compatibility. Stanford Medicine’s LCGM is on a mission to develop innovative manufacturing platforms for the GMP manufacture of cell and gene therapy products to bridge the “bench to bedside” gap for patients with large unmet medical needs. This aligns directly with Multiply Labs’ mission to enhance patient access to life-saving cell therapies by scaling availability through automation

Multiply Labs Announces Upcoming Collaboration With Stanford Medicine’S Laboratory For Cell And Gene Medicine (Lcgm) To Deploy Automated Systems For Cell Therapy Manufacturing

Cell isolation using immunomagnetic beads is a critical industry-standard process in cell therapy manufacturing. However, the current method of performing this task manually is complex and time-consuming. In addition to the sensitivity of cells, intricate process and precision required, the approach requires manually handling, connecting and double-checking complex closed-system consumable kits.By utilizing Multiply Labs' cell therapy robotic cluster and GenScript's GMP-grade CytoSinct 1000 cell isolation solution, capable of isolating up to 120X10^9 total cells within a single hour, this collaboration will introduce the first fully automated solution for bead-based cell isolation. Importantly, this automation technology will not require cell therapy manufacturers to make substantial modifications to their original manufacturing processes.This advancement promises to mitigate the risk of human error while simultaneously boosting cell therapy output. Once this part of the process can be run without human intervention, manufacturing operators and process scientists will be free to oversee the production of more therapies at once, without being tied down in the delicate, tedious, and mission-critical manual tasks involved in the traditional manufacturing process. Automation in this deeply time-consuming area of the process will therefore drive significant benefits around efficiency, and ultimately support the scalability of cell therapies."Our collaboration with Multiply Labs marks a significant advancement in personalized medicine and the potential impact of cell therapies," said Ray Chen, PhD, President of Life Science Group at GenScript

Multiply Labs And Genscript Biotech Corporation Collaborate To Automate The Cell Isolation And Enrichment Phase Of Cell Therapy Manufacturing

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.

Cell therapy weekly: Funding supports remyelination therapy for multiple sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function

Portal Biotechnologies And Multiply Labs Announce Partnership To Automate Cell Engineering In Cell Therapy Manufacturing

Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.

Multiply Labs inks $85m deal with Retro Bio to automate cell therapy manufacturing

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a biotechnology company developing therapies that meaningfully address age-related diseases, today announced a first-of-its-kind commercial and supply agreement valued at up to $85 million to automate Retro’s groundbreaking approach. Retro, supported by a recent investment by Sam Altman (CEO of OpenAI), is driven by a mission to extend healthy human lifespan by a decade, targeting the cellular drivers of aging. With this partnership, Multiply Labs marks the first commercial sale of its robotic system, in support of Retro’s efforts. This partnership underscores the versatility of Multiply Labs’ robotic systems, showcasing their wide range of cell therapy applications, which include but are not limited to CAR-T therapy manufacturing. The robotic systems can be used broadly to reduce costs, accelerate product timelines, and improve scalability for different types of cell therapies, as well as to automate manufacturing processes for both autologous and allogeneic therapies. By enabling Retro to manufacture at a cost-efficient scale, Multiply Labs empowers them to expedite the transition from process development to clinical trials and commercialization, ultimately expediting the development and delivery of life-changing therapies to patients worldwide

Multiply Labs And Retro Biosciences Announce An $85 Million Partnership To Advance Cell Therapy Manufacturing For Age-Related Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf, an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex® bioreactors. This collaboration is intended to provide the CGT field with easy-to-use high throughput ballroom manufacturing that reduces the need for highly skilled labor. The ultimate goal is to lower the barriers to widespread accessibility of potentially lifesaving cell and gene therapy drug products. G-Rex® closed system bioreactors simplify CGT manufacturing by providing cells with unlimited oxygen and nutrients on demand. Without the need for media or oxygen pumps, G-Rex® bioreactors function as an all-in-one stand-alone activation, transduction, expansion, and concentration device. This unique attribute is ideal for high throughput automated movement of G-Rex® bioreactors in a ballroom setting and for standardizing much of the CGT manufacturing process

Multiply Labs And Wilson Wolf Corporation Collaborate To Automate G-Rex(R) Bioreactor For Cell Therapy Manufacturing

Multiply Labs And Wilson Wolf Corporation Collaborate To Automate G-Rex® Bioreactor For Cell Therapy Manufacturing

Robotics company Multiply Labs has partnered with global life-sciences service provider Genscript Biotech to automate the cell isolation phase in cell therapy manufacturing.

Multiply Labs and GenScript partner on cell isolation automation

Creates personalized vitamins and supplements

Multiply Labs

Creates personalized vitamins and supplements

Multiply Labs

Creates personalized vitamins and supplements

About

Simplify's Take

What believers are saying

What critics are saying

What makes Multiply Labs unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

There are no jobs for Multiply Labs right now.